Permian Squibb submits Dapagliflozin interim data
-
Last Update: 2020-07-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
, a mid-term clinical trial of Dapagliflozin, a type 2 diabetes treatment drug, was presented at the annual meeting of the American Diabetes AssociationDapagliflozin is a sodium glucose absorption transporter 2 (SGLT-2) inhibitor that lowers blood sugar levels by preventing the reabsorption of glucoseIn Phase II clinical trials involving 47 patients, Dapagliflozin lowered blood sugar levels higher than the blank groupGiven the results of such clinical trials, a larger clinical trial will be conducted later this yearIndustry insiders estimate that Dapagliflozin will be licensed for the listing in 2010 and will generate annual sales of $300 million
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
